April 29, 2024 – Sunnyvale, California – Bright Biologics and Asieris Pharmaceutical have signed a collaboration agreement to advance the development of next-generation bispecific and trispecific antibody-drug conjugates (ADCs). This partnership will combine Asieris’ proprietary linker-payload technology with Bright’s innovative bispecific and trispecific antibodies to create and commercialize novel ADC therapies for cancer treatment.
About Asieris Pharmaceutical
Asieris Pharmaceutical is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative cancer therapies. The company specializes in targeted therapies, antibody-drug conjugates (ADCs), and proprietary drug delivery technologies.
Recognized for its expertise in linker-payload technology—a key component in next-generation ADC development—Asieris integrates cutting-edge science with strong research and development capabilities to enhance treatment efficacy and improve patient outcomes. It actively collaborates with biopharmaceutical firms, academic institutions, and research organizations to accelerate groundbreaking cancer treatments.
About Bright Biologics
Bright Biologics is a biotechnology company dedicated to advancing next-generation antibody-based therapies for cancer and other serious diseases. Specializing in bispecific and trispecific antibodies, as well as antibody-drug conjugates (ADCs), the company leverages advanced protein engineering and proprietary drug development platforms.
Focused on overcoming tumor resistance and enhancing treatment efficacy, Bright Biologics develops highly specific and potent biologics that simultaneously target multiple cancer-related antigens. This approach addresses key challenges in oncology, including tumor heterogeneity and antigen escape, which contribute to relapse.
The company collaborates with leading pharmaceutical firms, academic institutions, and research organizations to accelerate the development and commercialization of innovative biologics.
